NFKB1 and urinary bladder cancer: We also found regorafenib significantly reduces tumor growth, NF‐κB activation, and protein levels of tumor progression‐associated proteins (MMP‐9, XIAP, VEGF, and Cyclin‐D1) in bladder cancer in vitro and in vivo.